



ADCs: The New Frontier in NSCLC Treatment

Reshaping Non-Small Cell Lung Cancer Landscape

PRECISION MECHANISM & BIOMARKER TARGETS




HER2-MUTANT STANDARD OF CARE




T-DXd:
49-55%
RESPONSE RATES
in heavily pre-treated patients

TROP2 & HER3 EXPANSION


TROP2



HER3



THE "BYSTANDER EFFECT" ADVANTAGE



PRIMARY ADC TARGETS & TRIALS

TARGET	RELEVANT POPULATION	KEY CLINICAL TRIAL
HER2 Mutation	HER2 exon 20 insertions (2-3% of adenocarcinoma)	DESTINY-Lung01/02
TROP2	Broadly expressed; post-IO/chemo	TROPION-Lung01
HER3	High expression; post-osimertinib EGFR-mutant	HERTHENA-Lung01

SEVERITY-BASED ILD RESPONSE

GRADE 1



GRADE 2+



CLINICAL VIGILANCE & TOXICITY MANAGEMENT

MONITORING FOR ILD RISK:
12.4%
of patients

Requires active respiratory monitoring and CT baselines

OCULAR & HEME MANAGEMENT

